Compare Gilead Sciences, Inc. (GILD) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Under Armour Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Under Armour Inc Class A trades at $7.21 (market cap $2.89B). The key difference: Gilead Sciences, Inc. is far larger — about 56.6× Under Armour Inc Class A's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| GILD | UAA | |
|---|---|---|
Market Cap | $163.51B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $8.14 |
52-Week Low | $108.22 | $4.17 |
Enterprise Value | $178.05B | $4.52B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Under Armour (UAA) trades at $7.19, up 8.77% in the last session, with a bullish technical signal from moving averages and oscillators. The stock shows mixed fundamentals, with a negative net income margin of -9.98% and ROE of -30% for 2025, but beats earnings expectations in recent quarters. Cash flow trends are volatile, with a net outflow of $361.87M in 2025, while revenue declined to $5.16B. Analyst sentiment is cautious, with a consensus price target of $5.96 below the current price, and 58.11% hold ratings.
The outlook for UAA is challenged by weak North American sales and margin pressure, offset by international growth. Investment opportunity hinges on execution of a full-price strategy and cost control, but risks include consumer resistance and macroeconomic uncertainty. With the stock trading above the consensus target, near-term upside may be limited despite technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
